J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure

Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.